Krystal Biotech Inc (KRYS)
$213.66
+2.97
(+1.41%)▲
Performance
- $211.03$219.34$213.66
1.23%
Downside
Day's Volatility :3.79%
Upside
2.59%
- $93.95$214.98$213.66
56.03%
Downside
52 Weeks Volatility :56.3%
Upside
0.61%
Returns
| Period | Krystal Biotech Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 34.3% | 6.5% | 0.0% |
6 Months | 81.58% | 7.1% | 0.0% |
1 Year | 74.25% | 9.8% | 0.0% |
3 Years | 267.18% | 14.2% | -20.2% |
Highlights
Market Capitalization | 6.0B |
Book Value | $28.02 |
Earnings Per Share (EPS) | 2.21 |
PE Ratio | 95.33 |
Wall Street Target Price | 189.0 |
Profit Margin | 59.57% |
Operating Margin TTM | 12.85% |
Return On Assets TTM | -4.97% |
Return On Equity TTM | 8.87% |
Revenue TTM | 95.9M |
Revenue Per Share TTM | 3.45 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -50.6M |
Diluted Eps TTM | 2.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 2.33 |
EPS Estimate Next Year | 5.51 |
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Next Quarter | 0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 11.54%
Technicals Summary
Sell
Neutral
Buy
Krystal Biotech Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Krystal Biotech Inc | 15.64% | 81.58% | 74.25% | 267.18% | 353.39% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Krystal Biotech Inc | 95.33 | 95.33 | NA | 2.33 | 0.09 | -0.05 | NA | 28.02 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Krystal Biotech Inc | Buy | $6.0B | 353.39% | 95.33 | 59.57% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Institutional Holdings
FMR Inc
14.86%venBio Select Advisor LLC
8.95%Vanguard Group Inc
8.52%BlackRock Inc
6.32%Redmile Group, LLC
5.28%State Street Corporation
3.31%
Company Information
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Organization | Krystal Biotech Inc |
Employees | 229 |
CEO | Mr. Krish S. Krishnan M.B.A., M.S. |
Industry | Health Technology |
Discover More
Outfront Media Inc.
$213.66
+1.41%
Blackrock Short Duration Bond Etf
$213.66
+1.41%
Helmerich & Payne, Inc.
$213.66
+1.41%
Crane Nxt Co
$213.66
+1.41%
Liberty Global Plc - Class C Shares
$213.66
+1.41%
Waystar Holding Corp.
$213.66
+1.41%
Apogee Therapeutics
$213.66
+1.41%
Wd-40 Co
$213.66
+1.41%
Nnn Reit Inc.
$213.66
+1.41%